The SBRN [25] definition has also been used for individuals with mobility impairment, for example in studies of people with multiple sclerosis [33,34,35] and community-dwelling older adults (≥60 years of age) who self-reported mobility impairments [36]. The cut-point of ≤1.5 METs was ...
(NCCN) guidelines discuss molecular monitoring and response goals by line of therapy.42,46 The ELN 2020 recommendations state that the definition of response to 2L treatment should be the same as for 1L treatment with BCR::ABL1IS ≤10%, ≤1%, and ≤0.1% at 3, 6, and 12 months, ...